
Cytosorbents Reports Fourth Quarter And Full Year 2024 Financial Results And Recent Business Highlights
(MENAFN- PR Newswire) 2024 marked by strong commercial execution and improved operating leverage Company continues to expect DrugSorb-ATR regulatory decisions from Health Canada and US FDA in 2025 Successful Rights Offering and exercise of Series A Right …